Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(8):722-723;
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by O'Regan, R. M.
Right arrow Articles by Jordan, V. C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by O'Regan, R. M.
Right arrow Articles by Jordan, V. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 8, 722-723, April 21, 1999
© 1999 Oxford University Press

CORRESPONDENCE

RESPONSE: Re: Effects of the Antiestrogens Tamoxifen, Toremifene, and ICI 182,780 on Endometrial Cancer Growth

Ruth M. O'Regan, V. Craig Jordan

Affiliations of authors: Division of Medical Oncology and The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical Center, Chicago, IL.

Correspondence to: V. Craig Jordan, Ph.D., D.Sc., Robert H. Lurie Comprehensive Cancer Center, Olson Pavillion 8258, 303 East Chicago Ave., Chicago, IL 60611-3008.

Dr. Williams is to be congratulated for his persistence in pointing out the carcinogenicity of tamoxifen. This has stimulated critical laboratory research worldwide to show that the rat is a poor model to predict the risk of human liver cancer with tamoxifen. Originally, the animal data caused great concern, but the result in the laboratory was a paradox. After 20 . . . [Full Text of this Article]

NOTES

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?